Reuters logo
BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse
September 5, 2017 / 12:51 PM / 16 days ago

BRIEF-Bellerophon announces positive top line Phase 2 data of INOpulse

Sept 5 (Reuters) - Bellerophon Therapeutics Inc

* Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease

* Bellerophon Therapeutics Inc - ‍acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline​

* Bellerophon Therapeutics Inc - ‍study therapy was well tolerated with no related safety concerns​

* Bellerophon Therapeutics Inc - ‍is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension​

* Bellerophon Therapeutics Inc - ‍top-line data for Phase 3 trial of INOpulse expected in 2018​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below